GH Research PLC
Joshua Dawson House
Dawson Street
Dublin D02 RY95
Ireland
353 1 437 8334
https://www.ghres.com
版塊: Healthcare
行業: Biotechnology
全職員工: 49
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Mr. Florian Schonharting M.Sc. (Econ) | Co-Founder & Non-Executive Chairman of the Board | 無 | 無 | 1969 |
| Dr. Theis Terwey M.D. | Co-Founder & CEO | 無 | 無 | 1976 |
| Mr. Magnus Halle | Co-Founder & MD of Ireland | 無 | 無 | 1997 |
| Ms. Julie Ryan F.C.A. | Vice President of Finance | 無 | 無 | 1986 |
| Mr. Aaron Cameron M.B.A. | Chief Operating Officer | 無 | 無 | 1985 |
| Mr. Naoise Gaffney | VP & Head of Intellectual Property | 無 | 無 | 無 |
| Dr. Velichka Valcheva M.D. | Chief Medical Officer | 無 | 無 | 1975 |
描述
GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.
公司管治
截至 無 止，GH Research PLC 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。
